BACKGROUND: Blood donors are at risk of iron deficiency. We evaluated the effects of blood donation intensity on iron and hemoglobin (Hb) in a prospective study. STUDY DESIGN AND METHODS: Four cohorts of frequent and first-time or reactivated (FT/RA) blood donors (no donation in 2 years), female and male, totaling 2425, were characterized and followed as they donated blood frequently. At enrollment and the final visit, ferritin, soluble transferrin receptor (sTfR), and Hb were determined. Models to predict iron deficiency and Hb deferral were developed. Iron depletion was defined at two levels: iron deficiency erythropoiesis (IDE) [log(sTfR/ferritin) ≥ 2.07] and absent iron stores (AIS; ferritin < 12 ng/mL). RESULTS: Among returning female FT and RA donors, 20 and 51% had AIS and IDE at their final visit, respectively; corresponding proportions for males were 8 and 20%. Among female frequent donors who returned, 27 and 62% had AIS and IDE, respectively, while corresponding proportions for males were 18 and 47%. Predictors of IDE and/or AIS included a higher frequency of blood donation in the past 2 years, a shorter interdonation interval, and being female and young; conversely, taking iron supplements reduced the risk of iron depletion. Predictors of Hb deferral included female sex, black race, and a shorter interdonation interval. CONCLUSIONS: There is a high prevalence of iron depletion in frequent blood donors. Increasing the interdonation interval would reduce the prevalence of iron depletion and Hb deferral. Alternatively, replacement with iron supplements may allow frequent donation without the adverse outcome of iron depletion.
BACKGROUND: Blood donors are at risk of iron deficiency. We evaluated the effects of blood donation intensity on iron and hemoglobin (Hb) in a prospective study. STUDY DESIGN AND METHODS: Four cohorts of frequent and first-time or reactivated (FT/RA) blood donors (no donation in 2 years), female and male, totaling 2425, were characterized and followed as they donated blood frequently. At enrollment and the final visit, ferritin, soluble transferrin receptor (sTfR), and Hb were determined. Models to predict iron deficiency and Hb deferral were developed. Iron depletion was defined at two levels: iron deficiency erythropoiesis (IDE) [log(sTfR/ferritin) ≥ 2.07] and absent iron stores (AIS; ferritin < 12 ng/mL). RESULTS: Among returning female FT and RA donors, 20 and 51% had AIS and IDE at their final visit, respectively; corresponding proportions for males were 8 and 20%. Among female frequent donors who returned, 27 and 62% had AIS and IDE, respectively, while corresponding proportions for males were 18 and 47%. Predictors of IDE and/or AIS included a higher frequency of blood donation in the past 2 years, a shorter interdonation interval, and being female and young; conversely, taking iron supplements reduced the risk of iron depletion. Predictors of Hb deferral included female sex, black race, and a shorter interdonation interval. CONCLUSIONS: There is a high prevalence of iron depletion in frequent blood donors. Increasing the interdonation interval would reduce the prevalence of iron depletion and Hb deferral. Alternatively, replacement with iron supplements may allow frequent donation without the adverse outcome of iron depletion.
Authors: Celso Bianco; Gary Brittenham; Ronald O Gilcher; Victor R Gordeuk; James P Kushner; Merlyn Sayers; Linda Chambers; Richard B Counts; Cheryl Aylesworth; George Nemo; Barbara Alving Journal: Transfusion Date: 2002-06 Impact factor: 3.157
Authors: J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff Journal: Nat Genet Date: 1996-08 Impact factor: 38.330
Authors: Shrein H Bahrami; Anne M Guiltinan; Karen S Schlumpf; Erik Scott; Linda L Banks; Pam D'Andrea; Elizabeth L Hartman; Vibha Vij; David J Wright; Bryan Spencer; Edward L Murphy Journal: Transfusion Date: 2011-01-07 Impact factor: 3.157
Authors: Sheila Bandyopadhyay; Gary M Brittenham; Richard O Francis; James C Zimring; Eldad A Hod; Steven L Spitalnik Journal: Blood Transfus Date: 2017-03 Impact factor: 3.443
Authors: Joseph E Kiss; Donald Brambilla; Simone A Glynn; Alan E Mast; Bryan R Spencer; Mars Stone; Steven H Kleinman; Ritchard G Cable Journal: JAMA Date: 2015-02-10 Impact factor: 56.272
Authors: Alan E Mast; John C Langer; Yuelong Guo; Walter Bialkowski; Bryan R Spencer; Tzong-Hae Lee; Joseph Kiss; Ritchard G Cable; Donald Brambilla; Michael P Busch; Grier P Page Journal: Transfusion Date: 2020-03-12 Impact factor: 3.157
Authors: Ritchard G Cable; Rebecca J Birch; Bryan R Spencer; David J Wright; Walter Bialkowski; Joseph E Kiss; Jorge Rios; Barbara J Bryant; Alan E Mast Journal: Transfusion Date: 2017-07-13 Impact factor: 3.157
Authors: Tamir Kanias; Mars Stone; Grier P Page; Yuelong Guo; Stacy M Endres-Dighe; Marion C Lanteri; Bryan R Spencer; Ritchard G Cable; Darrell J Triulzi; Joseph E Kiss; Edward L Murphy; Steve Kleinman; Mark T Gladwin; Michael P Busch; Alan E Mast Journal: Transfusion Date: 2018-11-26 Impact factor: 3.157
Authors: Joseph E Kiss; Whitney R Steele; David J Wright; Alan E Mast; Patricia M Carey; Edward L Murphy; Jerry L Gottschall; Toby L Simon; Ritchard G Cable Journal: Transfusion Date: 2013-04-26 Impact factor: 3.157